<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041973</url>
  </required_header>
  <id_info>
    <org_study_id>MAL19001</org_study_id>
    <nct_id>NCT04041973</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)</brief_title>
  <acronym>PAL_Cambodia</acronym>
  <official_title>An Open-label Individually Randomised Controlled Trial to Assess the Efficacy of Artemether-lumefantrine Prophylaxis for Malaria Among Forest Goers in Cambodia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the Greater Mekong Subregion (GMS) adults are at highest risk for malaria. The most
      relevant disease vectors bite during daytime and outdoors which makes forest work a high-risk
      activity for malaria. The absence of effective vector control strategies and limited periods
      of exposure during forest visits suggest that chemoprophylaxis could be an appropriate
      strategy to protect forest workers against malaria.

      The investigators propose the use of Artemether-lumefantrine (AL), a drug whose efficacy
      remains high in the GMS, unlike, for example DHA/piperaquine [20]. The proposed study will
      help to assess the efficacy and feasibility of prophylaxis to prevent malaria in forest
      workers, help to identify the optimal regimen, and predict its efficacy in reducing overall
      transmission. The proposed study is a critical step for future use of chemoprophylaxis to
      protect forest workers in the GMS against malaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary of trial design

      An open-label randomised trial among forest goers comparing the ACT AL with a multivitamin
      with no antimalarial activity to evaluate the efficacy of prophylaxis, and to better
      understand high risk groups and locations of malaria transmission.

      Artemether-lumefantrine prophylaxis trial

      The study of AL versus a multivitamin will be a two-arm randomised open label comparative
      study. Laboratory assessments of malaria infection at baseline and days 28, 56, and 84 will
      be performed blind to treatment allocation and incidence of clinical cases during follow-up
      will be recorded.

      Activities/outcomes

      The main activity proposed is an in vivo clinical assessment of prophylaxis to prevent
      malaria in 4400 participant episodes in 50 villages in Stung Treng and Pursat Provinces,
      Cambodia. The subjects will be randomized in a one-to-one ratio between the ACT AL and a
      multivitamin preparation with no antimalarial activity.

      The study sites have been chosen based on current information on incidence of malaria, known
      predominance of malaria among forest goers, presence of an established clinical research
      programme and feasibility to perform the proposed research activities.

      Efficacy of AL ACT will be assessed through follow up visits every 28 days during a course of
      prophylaxis when temperature, symptom questionnaires, brief physical examinations, and
      malaria parasite PCR, lumefantrine levels, and, in selected individuals, parasite genetics
      will be performed. Episodes of confirmed clinical malaria among study participants at any
      time point between enrolment and follow-up will also be recorded.

      All the organisations in this collaboration will work closely with local counterparts
      including the National Malaria Control Programmes (NMCPs), non-governmental and other
      relevant organisations. Training is an integral part of this collaborative working
      relationship, and the building of local research capacity is an essential component of all
      research plans.

      All research-related activities, from study design, planning, implementation through to
      analysis and writing of reports will be performed jointly with local counterparts. Both
      on-the-job training and formal training will be provided when needed, in particular for Good
      Clinical Practice (GCP) skills.

      The close interaction between WHO and its regional offices will ensure that new knowledge is
      disseminated efficiently and effectively throughout the region.

      Study duration

      The recruitment phase of the study is expected to last 12 months following the intended start
      of recruitment in July 2019. Training and community sensitization will precede study
      execution for 3 months. Data management and analysis, sample analysis (PCR, parasite
      genetics, lumefantrine levels), mathematical modelling and report writing are expected to
      take about 5 months. Therefore, the total time to complete the study will be about 20 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day PCR positivity rate of Plasmodium infections of any species.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with confirmed clinical malaria of any species reported between day 0 and day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day, 56-day, and 84-day PCR Plasmodium positivity rate for each species</measure>
    <time_frame>28, 56 and, 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with confirmed malaria reported between day 0 and day 28 for each species</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of confirmed clinical malaria cases as reported to government health facilities and village malaria workers.surveillance data.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Kelch13 mutations and other genetic markers of antimalarial drug resistance of known functional significance.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and serious adverse events by study arms during the course of prophylaxis.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a. Number of people living in each village b. Number of people working in each reported location c. Number of people who have travelled to different locations within the preceding 2 months d. Number of people who have a mobile phone for their own use</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latitude and longitude of the study participant over time in decimal degrees as recorded every 10-30 minutes by a GPS logging device.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall prevalence of Plasmodium at baseline, stratified by season and risk factors.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 0, 28, 56 and 84 capillary blood levels of lumefantrine.</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of serological diagnostic markers of other infectious diseases.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4400</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>ACT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemether-lumefantrine (AL) x 3 days followed by 1 day per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multivitamin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multivitamin x 3 days followed by 1 day per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
    <description>One tablet AL contains 20 mg artemether and 120 mg lumefantrine
The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest.</description>
    <arm_group_label>ACT arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin</intervention_name>
    <description>One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.
The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest.</description>
    <arm_group_label>Multivitamin arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Male or female, adults aged between 16 and 65 years.

          -  Planning to travel to the forest within the next 72 hours and stay overnight.

          -  Written informed consent.

          -  Willingness and ability of the participants to comply with the study protocol for the
             duration of the study.

        Exclusion criteria

          -  For females: known pregnancy or breast feeding

          -  Participants who have received artemisinin or a derivative or an
             artemisinin-containing combination therapy (ACT) within the previous 7 days.

          -  History of allergy or known contraindication to artemisinins, lumefantrine or
             multivitamins

          -  Documented or claimed history of cardiac conduction problems

          -  Severe vomiting or diarrhoea

          -  Signs/symptoms of clinical malaria (febrile or history of fever in the previous 24
             hours) confirmed by RDT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard J Maude, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol Oxford Tropical Medicine Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard J Maude, M.D.</last_name>
    <phone>+66 (0) 2203 6333</phone>
    <phone_ext>7365</phone_ext>
    <email>Richard@tropmedres.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Worarat Khuenpetch</last_name>
    <phone>+66 (0)8 1818 4403</phone>
    <email>Worarat@tropmedres.ac</email>
  </overall_contact_backup>
  <reference>
    <citation>Guerra CA, Snow RW, Hay SI. A global assessment of closed forests, deforestation and malaria risk. Ann Trop Med Parasitol. 2006 Apr;100(3):189-204. Review.</citation>
    <PMID>16630376</PMID>
  </reference>
  <reference>
    <citation>Thanh PV, Van Hong N, Van Van N, Van Malderen C, Obsomer V, Rosanas-Urgell A, Grietens KP, Xa NX, Bancone G, Chowwiwat N, Duong TT, D'Alessandro U, Speybroeck N, Erhart A. Epidemiology of forest malaria in Central Vietnam: the hidden parasite reservoir. Malar J. 2015 Feb 19;14:86. doi: 10.1186/s12936-015-0601-y.</citation>
    <PMID>25880664</PMID>
  </reference>
  <reference>
    <citation>Erhart A, Ngo DT, Phan VK, Ta TT, Van Overmeir C, Speybroeck N, Obsomer V, Le XH, Le KT, Coosemans M, D'alessandro U. Epidemiology of forest malaria in central Vietnam: a large scale cross-sectional survey. Malar J. 2005 Dec 8;4:58.</citation>
    <PMID>16336671</PMID>
  </reference>
  <reference>
    <citation>Sanh NH, Van Dung N, Thanh NX, Trung TN, Van Co T, Cooper RD. Forest malaria in central Vietnam. Am J Trop Med Hyg. 2008 Nov;79(5):652-4.</citation>
    <PMID>18981498</PMID>
  </reference>
  <reference>
    <citation>Thang ND, Erhart A, Speybroeck N, Hung le X, Thuan le K, Hung CT, Ky PV, Coosemans M, D'Alessandro U. Malaria in central Vietnam: analysis of risk factors by multivariate analysis and classification tree models. Malar J. 2008 Jan 30;7:28. doi: 10.1186/1475-2875-7-28.</citation>
    <PMID>18234102</PMID>
  </reference>
  <reference>
    <citation>Erhart A, Thang ND, Hung NQ, Toi le V, Hung le X, Tuy TQ, Cong le D, Speybroeck N, Coosemans M, D'Alessandro U. Forest malaria in Vietnam: a challenge for control. Am J Trop Med Hyg. 2004 Feb;70(2):110-8.</citation>
    <PMID>14993619</PMID>
  </reference>
  <reference>
    <citation>Dysoley L, Kaneko A, Eto H, Mita T, Socheat D, Börkman A, Kobayakawa T. Changing patterns of forest malaria among the mobile adult male population in Chumkiri District, Cambodia. Acta Trop. 2008 Jun;106(3):207-12. doi: 10.1016/j.actatropica.2007.01.007. Epub 2008 Apr 7.</citation>
    <PMID>18471797</PMID>
  </reference>
  <reference>
    <citation>Moore SJ, Min X, Hill N, Jones C, Zaixing Z, Cameron MM. Border malaria in China: knowledge and use of personal protection by minority populations and implications for malaria control: a questionnaire-based survey. BMC Public Health. 2008 Oct 1;8:344. doi: 10.1186/1471-2458-8-344.</citation>
    <PMID>18828901</PMID>
  </reference>
  <reference>
    <citation>Gryseels C, Peeters Grietens K, Dierickx S, Xuan XN, Uk S, Bannister-Tyrrell M, Trienekens S, Ribera JM, Hausmann-Muela S, Gerrets R, D'Alessandro U, Sochantha T, Coosemans M, Erhart A. High Mobility and Low Use of Malaria Preventive Measures Among the Jarai Male Youth Along the Cambodia-Vietnam Border. Am J Trop Med Hyg. 2015 Oct;93(4):810-818. doi: 10.4269/ajtmh.15-0259. Epub 2015 Aug 17.</citation>
    <PMID>26283747</PMID>
  </reference>
  <reference>
    <citation>Grietens KP, Xuan XN, Ribera J, Duc TN, Bortel Wv, Ba NT, Van KP, Xuan HL, D'Alessandro U, Erhart A. Social determinants of long lasting insecticidal hammock use among the Ra-glai ethnic minority in Vietnam: implications for forest malaria control. PLoS One. 2012;7(1):e29991. doi: 10.1371/journal.pone.0029991. Epub 2012 Jan 12.</citation>
    <PMID>22253852</PMID>
  </reference>
  <reference>
    <citation>Lengeler C. Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst Rev. 2000;(2):CD000363. Review. Update in: Cochrane Database Syst Rev. 2004;(2):CD000363.</citation>
    <PMID>10796535</PMID>
  </reference>
  <reference>
    <citation>Thang ND, Erhart A, Speybroeck N, Xa NX, Thanh NN, Ky PV, Hung le X, Thuan le K, Coosemans M, D'Alessandro U. Long-Lasting Insecticidal Hammocks for controlling forest malaria: a community-based trial in a rural area of central Vietnam. PLoS One. 2009 Oct 7;4(10):e7369. doi: 10.1371/journal.pone.0007369.</citation>
    <PMID>19809502</PMID>
  </reference>
  <reference>
    <citation>Son DH, Thuy-Nhien N, von Seidlein L, Le Phuc-Nhi T, Phu NT, Tuyen NTK, Tran NH, Van Dung N, Van Quan B, Day NPJ, Dondorp AM, White NJ, Thwaites GE, Hien TT. The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study. Malar J. 2017 Nov 6;16(1):444. doi: 10.1186/s12936-017-2091-6.</citation>
    <PMID>29110709</PMID>
  </reference>
  <reference>
    <citation>York A. Seasonal malaria chemoprevention in the Sahel. Lancet Infect Dis. 2017 Jun;17(6):588. doi: 10.1016/S1473-3099(17)30255-4.</citation>
    <PMID>28555586</PMID>
  </reference>
  <reference>
    <citation>Snow RW. Seasonal Malaria Chemoprevention: An Evolving Research Paradigm. PLoS Med. 2016 Nov 22;13(11):e1002176. doi: 10.1371/journal.pmed.1002176. eCollection 2016 Nov.</citation>
    <PMID>27875534</PMID>
  </reference>
  <reference>
    <citation>Tripura R, Peto TJ, Chea N, Chan D, Mukaka M, Sirithiranont P, Dhorda M, Promnarate C, Imwong M, von Seidlein L, Duanguppama J, Patumrat K, Huy R, Grobusch MP, Day NPJ, White NJ, Dondorp AM. A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages. Clin Infect Dis. 2018 Aug 31;67(6):817-826. doi: 10.1093/cid/ciy196.</citation>
    <PMID>29522113</PMID>
  </reference>
  <reference>
    <citation>Imwong M, Hanchana S, Malleret B, Rénia L, Day NP, Dondorp A, Nosten F, Snounou G, White NJ. High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias. J Clin Microbiol. 2014 Sep;52(9):3303-9. doi: 10.1128/JCM.01057-14. Epub 2014 Jul 2.</citation>
    <PMID>24989601</PMID>
  </reference>
  <reference>
    <citation>Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, Suangkanarat P, Jeeyapant A, Vihokhern B, Wongsaen K, Van Hue D, Dong le T, Nguyen TU, Lubell Y, von Seidlein L, Dhorda M, Promnarate C, Snounou G, Malleret B, Rénia L, Keereecharoen L, Singhasivanon P, Sirithiranont P, Chalk J, Nguon C, Hien TT, Day N, White NJ, Dondorp A, Nosten F. The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. Malar J. 2015 Sep 30;14:381. doi: 10.1186/s12936-015-0906-x.</citation>
    <PMID>26424000</PMID>
  </reference>
  <reference>
    <citation>Saunders DL, Vanachayangkul P, Lon C; U.S. Army Military Malaria Research Program; National Center for Parasitology, Entomology, and Malaria Control (CNM); Royal Cambodian Armed Forces. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med. 2014 Jul 31;371(5):484-5. doi: 10.1056/NEJMc1403007.</citation>
    <PMID>25075853</PMID>
  </reference>
  <reference>
    <citation>West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet. 2018 Apr 7;391(10128):1378-1390. doi: 10.1016/S0140-6736(18)30291-5. Epub 2018 Mar 29.</citation>
    <PMID>29606364</PMID>
  </reference>
  <reference>
    <citation>Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair S, Tharyan P. Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014 Mar 4;(3):CD006404. doi: 10.1002/14651858.CD006404.pub2. Review. Update in: Cochrane Database Syst Rev. 2019 Jan 08;1:CD006404.</citation>
    <PMID>24596021</PMID>
  </reference>
  <reference>
    <citation>World Health Organization, WHO Model List of Essential Medicines. 2017.</citation>
  </reference>
  <reference>
    <citation>Agency, E.M., European Public Assessment Report for Pyramax. 2016.</citation>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

